CriticalSSRI (selective serotonin reuptake inhibitor)×Reversible MAO-A inhibitor (RIMA)
Updated · Methodology
Mechanism
Citalopram is a selective serotonin reuptake inhibitor (SSRI). Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of serotonin, noradrenaline and dopamine (moclobemide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). MAO inhibitors impair serotonin metabolism and raise the risk of life-threatening serotonin syndrome with SSRIs (citalopram label, US Food and Drug Administration, FDA). The Spanish citalopram SmPC reports cases of serotonin syndrome specifically with the combination of citalopram and moclobemide (citalopram SmPC, AEMPS). Moclobemide inhibits the enzyme CYP2C19, so levels of drugs metabolised by this enzyme may rise (moclobemide SmPC, AEMPS). CYP2C19 accounts for about 38% of the conversion of citalopram to demethylcitalopram (citalopram SmPC, AEMPS). According to the US label, CYP2C19 inhibitors increase the risk of QT prolongation and ventricular arrhythmias with citalopram (FDA citalopram label). The half-life of citalopram is about 33 hours (citalopram SmPC, AEMPS), and that of moclobemide is about 3 hours (moclobemide SmPC, AEMPS).
Symptoms
Serotonin syndrome may include mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, dizziness, sweating, flushing, hyperthermia), neuromuscular symptoms (tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, nausea, vomiting and diarrhoea (citalopram label, US Food and Drug Administration, FDA). Serious and sometimes fatal reactions have occurred when selective serotonin reuptake inhibitors were combined with monoamine oxidase inhibitors, moclobemide included. These reactions included hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid swings in vital signs, confusion, irritability and extreme agitation progressing to delirium and coma (citalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Isolated cases of hyperthermia, confusion, hyperreflexia and myoclonus have occurred when moclobemide was combined with antidepressants, citalopram among them (moclobemide SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish citalopram summary of product characteristics (SmPC) rules out citalopram in patients taking monoamine oxidase inhibitors (MAOIs) and lists the combination with reversible MAOIs, moclobemide included, among contraindicated combinations (citalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The citalopram label of the US Food and Drug Administration (FDA) contraindicates citalopram with MAOIs and within 14 days of stopping them (FDA citalopram label). The moclobemide SmPC is softer and lists citalopram among antidepressants to give with caution alongside moclobemide (moclobemide SmPC, AEMPS). When switching from moclobemide to citalopram, the interval follows the moclobemide SmPC (citalopram SmPC, AEMPS). The moclobemide SmPC allows another antidepressant the day after moclobemide is stopped (moclobemide SmPC, AEMPS). The US label asks for at least 14 days after an MAOI antidepressant (FDA citalopram label). When switching the other way, start moclobemide no earlier than 7 days (citalopram SmPC, AEMPS) or 14 days (FDA citalopram label) after stopping citalopram, taking into account the half-life of citalopram (moclobemide SmPC, AEMPS). Before stopping citalopram, taper the dose over at least 1–2 weeks (citalopram SmPC, AEMPS). If signs of serotonin syndrome appear, stop citalopram and other serotonergic drugs at once and start symptomatic treatment (citalopram SmPC, AEMPS, and FDA label). Keep the patient under medical observation, in hospital if needed (moclobemide SmPC, AEMPS). Warn the patient in advance about the risk of serotonin syndrome with MAOIs (FDA citalopram label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Citalopram, Seropram 30 mg (nº registro 63564) (2024)– AEMPS, CIMA, nº registro 63564 (Seropram 30 mg comprimidos recubiertos con película, Lundbeck), revisión 01/2024, secciones 4.2, 4.3, 4.4, 4.5 y 5.1
- FDA: Celexa (citalopram) – Prescribing Information (2023)– FDA, DailyMed SPL, Allergan, setid 4259d9b1-de34-43a4-85a8-41dd214e9177, version 40, revised 10/2023, sections 4, 5.2, 5.3, 5.4, 7, 12.3 and 17
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2